BioRay Pharmaceutical Co., Ltd.
16
2
5
3
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 100/100
31.3%
5 terminated/withdrawn out of 16 trials
37.5%
-49.0% vs industry average
6%
1 trials in Phase 3/4
0%
0 of 3 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (16)
Treatment of Orelabrutinib+Hi-CVP Regimen for Previously Untreated MZL
Role: collaborator
Clinical Trial of BR2251 Tablets for Patients With Primary Gout and Hyperuricemia
Role: lead
Clinical Study of BR105 Injection
Role: lead
Phase IIa Study of BRY812 Monotherapy in Advanced Gynecological Malignancies
Role: lead
A Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
Role: lead
A Phase I Study of BR108 in Hematological Malignancies
Role: lead
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel
Role: lead
A Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
Role: lead
Comparison of Pharmacokinetics and Safety of HS632 and Xolair® With a Single Injection
Role: lead
A Study of BR111 in Patients With Advanced Malignancies
Role: lead
A Study of BRY805 in Participants With Advanced Solid Tumors
Role: lead
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Role: lead
A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Role: lead
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
Role: lead
Phase I/II Clinical Study of 1A46 Drug Substance
Role: lead
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Role: lead
All 16 trials loaded